Profil
Harry Sacks worked as a Principal at Forest Laboratories, Inc. and as a Vice President-Clinical Development at Edge Therapeutics, Inc. He also worked as a VP-Medical Affairs & Medical Officer at OptiNose, Inc. from 2017 to 2022 and as a VP, Head-Respiratory & US Clinical Development at Novartis AG.
Dr. Sacks holds a doctorate degree from Albert Einstein College of Medicine, Inc.
Anciens postes connus de Harry Sacks
| Sociétés | Poste | Fin |
|---|---|---|
| OPTINOSE, INC. | Chief Tech/Sci/R&D Officer | 01/10/2022 |
| NOVARTIS AG | Chief Tech/Sci/R&D Officer | - |
Edge Therapeutics, Inc.
 Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | Corporate Officer/Principal | - |
| FOREST LABORATORIES, INC. | Corporate Officer/Principal | - |
Formation de Harry Sacks
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| OPTINOSE, INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| Entreprise privées | 2 |
|---|---|
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | Health Technology |
